Melanoma News and Research

Latest Melanoma News and Research

National Council on Skin Cancer Prevention 'Don't Fry Day' campaign to encourage sun safety awareness

Despite skin cancer's being largely preventable, it remains by far the most common type of cancer in the United States. There are over two million new cases of skin cancer diagnosed annually, which is more than new cases of breast, prostate, lung and colon cancers combined.

24 May 2011

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

The American Academy of Dermatology today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cancer.

24 May 2011

Exosome Diagnostics announces expansion of scientific advisory board

Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).

24 May 2011

Shave biopsies accurate in initial diagnosis of suspicious skin lesions

A shave biopsy is a reasonably safe and accurate method for the initial diagnosis of melanoma, according to a study published in the April issue of the Journal of the American College of Surgeons. In the past, some physicians have criticized shave biopsies for not providing accurate T (tumor) stage information, thereby complicating treatment planning.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Free skin cancer screenings for local community

The John Theurer Cancer Center at Hackensack University Medical Center's Cutaneous Malignancies Program has partnered with The Promise Foundation to host a skin cancer screening event on Thursday, June 2 from 10am -5pm. This program will feature educational information on skin cancer prevention and offer free skin cancer screenings by appointment only for the community.

21 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

Use of a simple, at-home screening test by Canadians can prevent many unnecessary colorectal cancer deaths, according to a special report about colorectal cancer in Canadian Cancer Statistics 2011 released today by the Canadian Cancer Society, in collaboration with the Public Health Agency of Canada and Statistics Canada.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

A new study links the intermittent interruption of breathing that occurs in patients with obstructive sleep apnea to enhanced proliferation of melanoma cancer cells and increased tumor growth in mice, according to researchers in Spain.

18 May 2011

Leucine deprivation triggers apoptosis in melanoma cells

Whitehead Institute researchers have found that depriving human melanoma cells of the essential amino acid leucine can be lethal to the cells, suggesting a possible strategy for therapeutic intervention.

18 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

IsoRay third fiscal quarter sales increase 17%

IsoRay Inc., announced financial results for the third fiscal quarter ended March 31, 2011 underscoring significant improvements in quarterly sales revenue growth both sequentially and in the prior year quarter. Sales increased 17% in the period with the Company posting a 581% gain in gross profit compared to the prior year third quarter.

16 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Melanoma News and Research

Latest Melanoma News and Research

National Council on Skin Cancer Prevention 'Don't Fry Day' campaign to encourage sun safety awareness

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

Exosome Diagnostics announces expansion of scientific advisory board

Shave biopsies accurate in initial diagnosis of suspicious skin lesions

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Wills Eye Institute and Thomas Jefferson University create new vision research center

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Free skin cancer screenings for local community

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

Leucine deprivation triggers apoptosis in melanoma cells

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

IsoRay third fiscal quarter sales increase 17%

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Melanoma News and Research

Latest Melanoma News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in